New RA drug enters human safety testing

NCT ID NCT07433335

First seen Mar 02, 2026 · Last updated May 11, 2026 · Updated 10 times

Summary

This early-stage study tests a new medicine called SR-878 in 27 adults with rheumatoid arthritis. The goal is to find a safe dose by checking for side effects. Participants will take the drug once and be monitored for about 16 weeks. This is not a cure; it aims to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • SciRhom clinical trial site

    NOT_YET_RECRUITING

    Tbilisi, Georgia

  • SciRhom clinical trial site

    RECRUITING

    Chisinau, Moldova

  • SciRhom clinical trial site

    NOT_YET_RECRUITING

    Bucharest, Romania

  • SciRhom clinical trial site

    NOT_YET_RECRUITING

    Cluj-Napoca, Romania

Conditions

Explore the condition pages connected to this study.